Top

memo - Magazine of European Medical Oncology

Published in:

01-09-2021 | Multiple Myeloma | original report

Effect of the ABO blood groups on the development, clinical features and survival of multiple myeloma

Authors: Mesut Göçer, M.D, Erdal Kurtoğlu

Published in: memo - Magazine of European Medical Oncology | Issue 3/2021

Summary

Background

Multiple myeloma (MM) is a cytogenetically heterogeneous and incurable plasma cell disease with unknown etiology. It is thought that the ABO blood groups may play a role in the etiology of many diseases. The purpose of this study is to determine whether there is a relationship between the ABO blood groups and the development of MM, clinical findings and overall survival.

Methods

In this single-center, retrospective and observational study, 198 patients with known blood types who diagnosed with MM between January 2012 and June 2020 were included.

Results

It was shown that individuals with blood group 0 had a significantly lower risk of MM (OR = 0.575, 95% confidence interval 0.416–0.794, P = 0.001). The incidence of extramedullary lesion was significantly higher in those with 0 blood group compared to other blood groups (P = 0.000). Overall survival was significantly shorter in patients with 0 blood group than those without 0 blood group (P = 0.007).

Conclusion

Individuals with 0 blood group had a lower risk of developing MM. It was determined that having 0 blood group is a predisposing factor for the development of extramedullary lesion in MM patients. However, it was shown that having a blood group of 0 was a very significant prognostic factor for MM patients and was associated with short OS.

Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. https://doi.org/10.4065/78.1.21.CrossRefPubMed

Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52–iv61. https://doi.org/10.1093/annonc/mdx096.CrossRefPubMed

Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20(4):637–64. https://doi.org/10.1016/j.beha.2007.08.001.CrossRefPubMed

Bird JM, Owen RG, D’Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011;154(1):32–75. https://doi.org/10.1111/j.1365-2141.2011.08573.x.CrossRefPubMed

Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–30. https://doi.org/10.1093/annonc/mdp329.CrossRefPubMed

Siransy LK, Nanga ZY, Zaba FS, Tufa NY, Dasse SR. ABO/rh blood groups and risk of HIV infection and hepatitis B among blood donors of Abidjan, Côte D’Ivoire. Eur J Microbiol Immunol. 2015;5(3):205–9. https://doi.org/10.1556/1886.2015.00029.CrossRef

Lesky E. Viennese serological research about the year 1900: its contribution to the development of clinical medicine. Bull N Y Acad Med. 1973;49(2):100–11.PubMedPubMedCentral

Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion. 2003;38(10):975–88. https://doi.org/10.1046/j.1537-2995.1998.381098440863.x.CrossRef

Breimer ME, Mölne J, Norden G, Rydberg L, Thiel G, Svalander CT. Blood group A and B antigen expression in human kidneys correlated to A1/A2/B, Lewis, and secretor status. Transplantation. 2006;82(4):479–85. https://doi.org/10.1097/01.tp.0000231697.15817.51.CrossRefPubMed

10.

Beardmore JA, Karimi-Booshehri F. ABO genes are differentially distributed in socio-economic groups in England. Nature. 1983;303(5917):522–4. https://doi.org/10.1038/303522a0.CrossRefPubMed

11.

Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV‑2 pneumonia. Br J Haematol. 2020;190(1):24–7. https://doi.org/10.1111/bjh.16797.CrossRefPubMed

12.

Aird I, Bentall HH, Roberts JAF. A relationship between cancer of stomach and the ABO blood groups. Br Med J. 1953;1(4814):799–801. https://doi.org/10.1136/bmj.1.4814.799.CrossRefPubMedPubMedCentral

13.

Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009;101(6):424–31. https://doi.org/10.1093/jnci/djp020.CrossRefPubMedPubMedCentral

14.

Wang Z, Liu L, Ji J, et al. Abo blood group system and gastric cancer: a case-control study and meta-analysis. Int J Mol Sci. 2012;13(10):13308–21. https://doi.org/10.3390/ijms131013308.CrossRefPubMedPubMedCentral

15.

Vadivelu MK, Damodaran S, Solomon J, Rajaseharan A. Distribution of ABO blood groups in acute leukaemias and lymphomas. Ann Hematol. 2004;83(9):584–7. https://doi.org/10.1007/s00277-004-0888-1.CrossRefPubMed

16.

Guleria K, Singh HP, Kaur H, Sambyal V. ABO blood groups in gastrointestinal tract (GIT) and breast carcinoma patients. Anthropologist. 2005;7(3):189–92. https://doi.org/10.1080/09720073.2005.11890905.CrossRef

17.

Rashaduz Z, Mohammad P, Md J, Mohammed AS. Study of ABO and Rh‑D blood group among the common people of Chittagong city corporation area of Bangladesh. J Public Health Epidemiol. 2015;7(9):305–10. https://doi.org/10.5897/jphe2015.0727.CrossRef

18.

Osada Y, Ito C, Nishiyama-Fujita Y, et al. Prognostic impact of ABO blood group on survival in patients with malignant lymphoma. Clin Lymphoma Myeloma Leuk. 2019;20(2):122–9. https://doi.org/10.1016/j.clml.2019.09.607.CrossRefPubMed

19.

Reid ME, Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol. 2004;41(2):93–117. https://doi.org/10.1053/j.seminhematol.2004.01.001.CrossRefPubMed

20.

Hakomori SI. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta. 1999;1473(1):247–66. https://doi.org/10.1016/S0304-4165(99)00183-X.CrossRefPubMed

21.

Ohira T, Cushman M, Tsai MY, et al. ABO blood group, other risk factors and incidence of venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). J Thromb Haemost. 2007;5(7):1455–61. https://doi.org/10.1111/j.1538-7836.2007.02579.x.CrossRefPubMed

22.

Hughes M, Doig A, Soutar R. Solitary plasmacytoma and multiple myeloma: adhesion molecule and chemokine receptor expression patterns. Br J Haematol. 2007;137(5):486–7. https://doi.org/10.1111/j.1365-2141.2007.06599.x.CrossRefPubMed

23.

Palumbo A, Avet-loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–9. https://doi.org/10.1200/JCO.2015.61.2267.CrossRefPubMedPubMedCentral

24.

Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med. 1989;110(7):521–5. https://doi.org/10.7326/0003-4819-110-7-521.CrossRefPubMed

25.

Ben Q, Wang K, Yuan Y, Li Z. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer. 2011;128(5):1179–86. https://doi.org/10.1002/ijc.25426.CrossRefPubMed

Title: Effect of the ABO blood groups on the development, clinical features and survival of multiple myeloma
Authors: Mesut Göçer, M.D
Erdal Kurtoğlu
Publication date: 01-09-2021
Publisher: Springer Vienna
Keyword: Multiple Myeloma
Published in: memo - Magazine of European Medical Oncology / Issue 3/2021
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-020-00669-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2021

Rehabilitation for children and adolescents after cancer: importance and implementation in Austria

Innovative therapy concepts for pediatric brain tumors

Sphenoidal mucormycosis associated with large B-cell lymphoma: case report and literature review

Therapy concepts in the context of precision medicine for pediatric malignancies—children are not adults

Lethal human metavirus pneumonia in a patient with chronic lymphocytic leukemia

Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer